Loading
The guideline that defined how trials decide a tumour has shrunk, stayed stable or grown, using the longest diameter of a few measured lesions, so results from different trials can be compared.
RECIST (Response Evaluation Criteria in Solid Tumours) was drawn up by the EORTC, the US National Cancer Institute and the National Cancer Institute of Canada to replace the older WHO criteria, which used two perpendicular diameters. RECIST measures only the longest diameter of each target lesion and sums them: a partial response is a decrease of at least 30% in the sum, progressive disease an increase of at least 20%, and stable disease anything between. It set rules for which lesions are measurable, how many to follow and how to confirm responses, and its revision as RECIST 1.1 in 2009 reduced the number of target lesions and added rules for lymph nodes.
Almost every response rate and progression-free survival figure quoted on this site rests on RECIST. Knowing that a partial response means a 30% shrinkage of a few measured lesions, not a cure, helps read trial results honestly, and the criteria's limits with immunotherapy led to iRECIST for delayed and mixed responses.
Shares Partial response, Complete response, RECIST.
Shares Partial response, Complete response, Objective response rate (ORR).
Shares Progressive disease and radiographic progression, RECIST, Objective response rate (ORR).
Shares Partial response, Complete response.
Shares Partial response, Complete response, RECIST.
Shares RECIST, Objective response rate (ORR).
Shares RECIST, Objective response rate (ORR).